HC Wainwright Has Pessimistic Outlook of AQST Q3 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Aquestive Therapeutics in a research note issued to investors on Tuesday, February 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.16) per share for the quarter, down from their previous forecast of ($0.15). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.61) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $12.81 million during the quarter, compared to the consensus estimate of $12.94 million.

Several other research firms have also weighed in on AQST. Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Zacks Research raised Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Wall Street Zen lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, JMP Securities increased their price target on Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a research note on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $8.50.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.00 on Thursday. The stock has a market cap of $488 million, a P/E ratio of -5.63 and a beta of 1.65. The company has a fifty day moving average price of $5.14 and a two-hundred day moving average price of $5.21. Aquestive Therapeutics has a one year low of $2.12 and a one year high of $7.55.

Institutional Trading of Aquestive Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $5,918,000. Pale Fire Capital SE raised its position in shares of Aquestive Therapeutics by 25.5% in the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock valued at $5,549,000 after buying an additional 340,767 shares in the last quarter. Sio Capital Management LLC boosted its stake in shares of Aquestive Therapeutics by 141.9% in the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock valued at $3,136,000 after buying an additional 555,860 shares during the period. Diametric Capital LP acquired a new stake in Aquestive Therapeutics during the second quarter worth approximately $547,000. Finally, Everstar Asset Management LLC increased its stake in Aquestive Therapeutics by 119.5% during the 2nd quarter. Everstar Asset Management LLC now owns 658,607 shares of the company’s stock worth $2,180,000 after acquiring an additional 358,607 shares during the period. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.